Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

24-07-22	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
21-12-09	TearLab Corporation Announces Board Appointments	CI
21-12-09	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
21-11-09	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
21-09-16	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
20-07-28	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
20-07-08	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
20-07-08	TearLab Corporation to Seek Acquisitions	CI
20-06-26	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-05-11	TearLab Corporation Announces Board Appointments	CI
20-05-11	Tearlab Mulls Inorganic Growth Opportunities	CI
20-05-10	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
20-05-10	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

20-07-09	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-26	TearLab: 1Q Earnings Snapshot	AQ
20-06-26	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
20-06-08	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
20-05-29	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	2026-03-31
Benjamin D. Sullivan CTO	Chief Tech/Sci/R&D Officer	-	2009-07-16
John Lund DFI	Director of Finance/CFO	60	2022-06-30

Director	Title	Age	Since
Richard Lindstrom BRD	Director/Board Member	78	2004-08-31
James V. Mazzo CHM	Chairman	68	2021-12-08
Uri Geiger BRD	Director/Board Member	58	2020-07-08

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/9/20	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%
7/9/20	Anthony Altig	Tender	Director	10,499	0.0430%
7/9/20	Richard Lindstrom	Tender	Director	27,444	0.1124%

TearLab Corporation Stock

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ESSILORLUXOTTICA	+1.96%	+1.63%	-31.50%	-6.53%	86.47B
ALCON INC.	+1.47%	+1.22%	-22.30%	-23.65%	33.18B
THE COOPER COMPANIES, INC.	+2.52%	+1.48%	-1.17%	-26.74%	13.71B
LENSKART SOLUTIONS LIMITED	-3.03%	+1.02%	-	-	10.37B
SHANGHAI CONANT OPTICAL CO., LTD.	-2.24%	-1.76%	-33.73%	+479.20%	1.8B
AUTEK CHINA INC.	-0.46%	-2.17%	-39.98%	-68.44%	1.44B
MINGYUE OPTICAL LENS CO.,LTD.	+0.40%	-2.46%	-39.44%	-31.39%	818M
PEGAVISION CORPORATION	-4.29%	-3.43%	+0.62%	-14.19%	803M
MENICON CO., LTD.	+0.51%	+6.55%	+50.64%	-30.36%	800M
Average	-0.26%	+0.87%	-14.61%	+34.74%	16.6B
Weighted average by Cap.	+1.44%	+1.06%	-25.82%	-7.28%